article: PMC7047557](/pmc/articles/PMC7047557/)\] \[[PubMed: 12519617](https://pubmed.ncbi.nlm.nih.gov/12519617)\] 15. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001 Jun;119(6):1661-70. \[[PubMed: 11399688](https://pubmed.ncbi.nlm.nih.gov/11399688)\] 16. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD006829. \[[PMC free article: PMC4170910](/pmc/articles/PMC4170910/)\] \[[PubMed: 22972099](https://pubmed.ncbi.nlm.nih.gov/22972099)\] 17. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Aug 30;2013(8):CD006826. \[[PMC free article: PMC6486274](/pmc/articles/PMC6486274/)\] \[[PubMed: 23990350](https://pubmed.ncbi.nlm.nih.gov/23990350)\] 18. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011 May;163(1):53-67. \[[PMC free article: PMC3085868](/pmc/articles/PMC3085868/)\] \[[PubMed: 21232047](https://pubmed.ncbi.nlm.nih.gov/21232047)\] 19. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ., M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009 Aug 29;374(9691):685-94. \[[PubMed: 19716960](https://pubmed.ncbi.nlm.nih.gov/19716960)\] 20. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014 May;2(5):361-8. \[[PubMed: 24746000](https://pubmed.ncbi.nlm.nih.gov/24746000)\] 21. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J, Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR., COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 Aug 25;365(8):689-98. \[[PMC free article: PMC3220999](/pmc/articles/PMC3220999/)\] \[[PubMed: 21864166](https://pubmed.ncbi.nlm.nih.gov/21864166)\] 22. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 2007 Dec;132(6):1741-7. \[[PubMed: 17646228](https://pubmed.ncbi.nlm.nih.gov/17646228)\] 23. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb 23;2015(2):CD003793. \[[PMC free article: PMC10008021](/pmc/articles/PMC10008021/)\] \[[PubMed: 25705944](https://pubmed.ncbi.nlm.nih.gov/25705944)\] 24. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive